2025 IVD Rohmaterial Maartfuerschungsbericht

ech. Market size and growth trend

The global IVD (in vitro diagnostic) reagent raw material market has shown strong growth in recent years. The global market size was approximately $81.7 Milliarden an 2024 and is expected to exceed the $100 billion mark by 2025, with a compound annual growth rate (CAGR) vun 4.3% vun 2025 zu 2031. China’s market performance stands out, with the domestic IVD market size reaching 120 billion yuan in 2024 and projected to maintain an 8.99% growth rate in 2025, far surpassing the global average. This growth is primarily attributed to population aging, rising incidence of chronic diseases and infectious diseases, as well as the sustained demand for rapid diagnostics driven by the post-COVID-19 era.

In terms of sub-sectors, biological reagents (such as antibodies and antigens) dominate the market with a share of more than 60%, while molecular diagnostics and POCT (Point-of-care Testen) are the fastest growing, with an expected growth rate of more than 7% in the next five years.

2. Regional market pattern

North America remains the world’s largest consumer market (Rechnung fir 38.19%), followed by Europe (25%). Asien-Pazifik Regioun, with China at its core, is rapidly rising, capturing over 20% of the global share. Under policy support, Chinese companies are accelerating their substitution of imported products, particularly in high-end raw materials, gradually narrowing the gap with multinational giants like Roche and Abbott.

Drëtten, technology and innovation drive

Technological innovation is the core driving force for industry growth:

High sensitivity technology: the demand for high purity buffer and enzyme labeling has increased, which promotes the upgrade of raw material quality.

Multiple detection technologies: The development of multiple raw materials is required, wéi PCR, NGS(next generation sequencing) and other technologies to promote the demand for molecular diagnostic raw materials.

Green trend: enterprises accelerate research and development of low pollution, degradable raw materials to meet international standards.

3. Policies and competitive patterns

Politik Ënnerstëtzung: China’s “Healthy China 2030” plan and other policies encourage innovation, and local governments promote the development of the industry through tax breaks and industrial funds.

Centralized procurement pressure: The centralized procurement of IVD reagents in China has led to a price drop of more than 50%. Enterprises have reduced costs and increased efficiency through mergers and acquisitions. An 2024, there were 43 domestic mergers and acquisitions cases, with an increase of 66.67% year-on-year.

International competition: multinational enterprises dominate the high-end market through technology monopoly, while local enterprises such as Mindray Medical and BGI enhance their competitiveness through technology feeding back and global layout.

4. Challenges and future trends

Erausfuerderungen: High R&D costs, strict regulation, market price sensitivity of emerging markets, combined with the pressure of centralized procurement, and squeezed corporate profit margins.

trend:

Technologie Integratioun: Emerging fields such as AI-assisted diagnosis and nanotechnology are driving the upgrade of raw materials.

International layout: Chinese raw material enterprises accelerate their overseas expansion and expand emerging markets through cooperation or mergers and acquisitions.

POCT expansion: The POCT raw material market is expected to grow to $29.5 Milliarde vun 2030, making it the fastest growing segment.

Epilogue

The IVD raw material market has a promising future driven by technological iteration, policy dividends and demand expansion, but companies need to cope with cost pressures and international competition. An Zukunft, companies with innovative capabilities, compliant production and global vision will dominate.

Fournisseur

Shanghai Lingjun Biotechnology Co., Ltd., Ltd.gouf etabléiert an 2016 deen e professionnelle Hiersteller vu biomagnetesche Materialien an Nukleinsäure Extraktiounsreagenz ass.

Mir hu räich Erfahrung an Nukleinsäure Extraktioun an Offäll, Protein Reinigung, Zell Trennung, Chemilumineszenz, an aner technesch Beräicher.

Eis Produkter gi wäit a ville Beräicher benotzt, wéi medizinesch Tester, genetesch Tester, Universitéit Fuerschung, genetesch Zucht, an esou weider. Mir bidden net nëmmen Produkter, awer och kënnen OEM ënnerhuelen, ODM, an aner Besoinen. Wann Dir e verbonne Besoin hutt, weg fillen gratis eis ze kontaktéieren .